Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2013 1
2014 4
2015 3
2016 4
2017 1
2018 2
2019 4
2020 6
2021 6
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for stephan tschirdewahn
Your search for Stephan Schirdewahn retrieved no results
[Upper urinary tract cancer].
Tschirdewahn S, Rübben H. Tschirdewahn S, et al. Urologe A. 2019 Jan;58(1):3-4. doi: 10.1007/s00120-018-0827-8. Urologe A. 2019. PMID: 30666375 German. No abstract available.
Serum and tissue syndecan-1 levels in renal cell carcinoma.
Niedworok C, Kempkensteffen C, Eisenhardt A, Tschirdewahn S, Rehme C, Panic A, Reis H, Baba H, Nyirády P, Hadaschik B, Kovalszky I, Szarvas T. Niedworok C, et al. Among authors: tschirdewahn s. Transl Androl Urol. 2020 Jun;9(3):1167-1176. doi: 10.21037/tau-19-787. Transl Androl Urol. 2020. PMID: 32676400 Free PMC article.
Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography-fusion Biopsy.
Tschirdewahn S, Wiesenfarth M, Bonekamp D, Püllen L, Reis H, Panic A, Kesch C, Darr C, Heß J, Giganti F, Moore CM, Guberina N, Forsting M, Wetter A, Hadaschik B, Radtke JP. Tschirdewahn S, et al. Eur Urol Focus. 2021 Nov;7(6):1300-1307. doi: 10.1016/j.euf.2020.06.020. Epub 2020 Jul 11. Eur Urol Focus. 2021. PMID: 32660838
Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.
Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik B, Olah C, Krege S, Nyirády P, Szendröi A, Szücs M, Módos O, Székely E, Reis H, Szarvas T. Krafft U, et al. Among authors: tschirdewahn s. Urol Oncol. 2019 Nov;37(11):810.e7-810.e15. doi: 10.1016/j.urolonc.2019.04.015. Epub 2019 Apr 30. Urol Oncol. 2019. PMID: 31053526
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics.
Kesch C, Yirga L, Dendl K, Handke A, Darr C, Krafft U, Radtke JP, Tschirdewahn S, Szarvas T, Fazli L, Gleave M, Giesel FL, Haberkorn U, Hadaschik B. Kesch C, et al. Among authors: tschirdewahn s. Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):385-389. doi: 10.1007/s00259-021-05423-y. Epub 2021 Jul 5. Eur J Nucl Med Mol Imaging. 2021. PMID: 34226953 Free PMC article.
27 results